Company Description
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.
In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation.
Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University.
The company was incorporated in 1987 and is headquartered in Fitzroy, Australia.
| Country | Australia |
| Founded | 1989 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Simon Morriss |
Contact Details
Address: 60-66 Hanover Street Fitzroy, VIC 3065 Australia | |
| Phone | 61 3 8412 7000 |
| Website | genetype.com |
Stock Details
| Ticker Symbol | GENE |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001166272 |
| CUSIP Number | 37185R208 |
| ISIN Number | US37185R4065 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kevin Camilleri | Chief Executive Officer of EasyDNA |
| Simon Morriss | Chief Executive Officer |
| Mark Ziirsen | Chief Financial Officer and Company Secretary |
| Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA | Consultant |
| Dr. Erika Spaeth Ph.D. | Director of Clinical and Scientific Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 6-K | Report of foreign issuer |
| Oct 28, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Sep 11, 2024 | 6-K | Report of foreign issuer |
| Aug 28, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | 6-K | Report of foreign issuer |
| Jul 31, 2024 | 6-K | Report of foreign issuer |